AstraZeneca PLC (AZN)vsCartesian Therapeutics Inc. (RNAC)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
RNAC
Cartesian Therapeutics Inc.
$6.22
-3.86%
HEALTHCARE · Cap: $199.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2099971% more annual revenue ($58.74B vs $2.80M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
RNAC
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+29.3%
Fair Value
$9.07
Current Price
$6.22
$2.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
16.8% revenue growth
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -7029.0% — below average capital efficiency
Earnings declined 7.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : RNAC
The strongest argument for RNAC centers on Revenue Growth. Revenue growth of 16.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : RNAC
The primary concerns for RNAC are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while RNAC is a growth play — different risk/reward profiles.
RNAC carries more volatility with a beta of 0.56 — expect wider price swings.
RNAC is growing revenue faster at 16.8% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 18/100), backed by strong 17.4% margins. RNAC offers better value entry with a 29.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cartesian Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?